Literature DB >> 17548888

Development of a novel method to determine very low density lipoprotein kinetics.

Iqbal A R Al-Shayji1, Jason M R Gill, Josephine Cooney, Samira Siddiqui, Muriel J Caslake.   

Abstract

Isotopic tracer methods of determining triglyceride-rich lipoprotein (TRL) kinetics are costly, time-consuming, and labor-intensive. This study aimed to develop a simpler and cost-effective method of obtaining TRL kinetic data, based on the fact that chylomicrons compete with large VLDL (VLDL(1); S(f) = 60-400) for the same catalytic pathway. Ten healthy subjects [seven men; fasting triglyceride (TG), 44.3-407.6 mg/dl; body mass index, 21-35 kg/m(2)] were given an intravenous infusion of a chylomicron-like TG emulsion (Intralipid; 0.1 g/kg bolus followed by 0.1 g/kg/h infusion) for 75-120 min to prevent the clearance of VLDL(1) by lipoprotein lipase. Multiple blood samples were taken during and after infusion for separation of Intralipid, VLDL(1), and VLDL(2) by ultracentrifugation. VLDL(1)-apolipoprotein B (apoB) and TG production rates were calculated from their linear increases in the VLDL(1) fraction during the infusion. Intralipid-TG clearance rate was determined from its exponential decay after infusion. The production rates of VLDL(1)-apoB and VLDL(1)-TG were (mean +/- SEM) 25.4 +/- 3.9 and 1,076.7 +/- 224.7 mg/h, respectively, and the Intralipid-TG clearance rate was 66.9 +/- 11.7 pools/day. Kinetic data obtained from this method agree with values obtained from stable isotope methods and show the expected relationships with indices of body fatness and insulin resistance (all P < 0.05). The protocol is relatively quick, inexpensive, and transferable to nonspecialist laboratories.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17548888     DOI: 10.1194/jlr.D600044-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  8 in total

1.  Quantifying apoprotein synthesis in rodents: coupling LC-MS/MS analyses with the administration of labeled water.

Authors:  Haihong Zhou; Wenyu Li; Sheng-Ping Wang; Vivienne Mendoza; Raymond Rosa; James Hubert; Kithsiri Herath; Theresa McLaughlin; Rory J Rohm; Michael E Lassman; Kenny K Wong; Douglas G Johns; Stephen F Previs; Brian K Hubbard; Thomas P Roddy
Journal:  J Lipid Res       Date:  2012-03-03       Impact factor: 5.922

Review 2.  The combined hyperlipidemia caused by impaired Wnt-LRP6 signaling is reversed by Wnt3a rescue.

Authors:  Gwang-Woong Go; Roshni Srivastava; Antonio Hernandez-Ono; Gyoungok Gang; Stephen B Smith; Carmen J Booth; Henry N Ginsberg; Arya Mani
Journal:  Cell Metab       Date:  2014-02-04       Impact factor: 27.287

3.  Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size.

Authors:  Daniël B van Schalkwijk; Albert A de Graaf; Ben van Ommen; Kees van Bochove; Patrick C N Rensen; Louis M Havekes; Niek C A van de Pas; Huub C J Hoefsloot; Jan van der Greef; Andreas P Freidig
Journal:  J Lipid Res       Date:  2009-06-10       Impact factor: 5.922

4.  Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids.

Authors:  Mirjana Pavlic; Changting Xiao; Linda Szeto; Bruce W Patterson; Gary F Lewis
Journal:  Diabetes       Date:  2009-12-22       Impact factor: 9.461

Review 5.  Hyperlipoproteinemia type 3: the forgotten phenotype.

Authors:  Paul N Hopkins; Eliot A Brinton; M Nazeem Nanjee
Journal:  Curr Atheroscler Rep       Date:  2014-09       Impact factor: 5.113

6.  Stable isotope-labeled tracers for the investigation of fatty acid and triglyceride metabolism in humans in vivo.

Authors:  Faidon Magkos; Bettina Mittendorfer
Journal:  Clin Lipidol       Date:  2009-04-01

7.  Measurement of intraorgan fat and hepatic output of triglycerides in human type 2 diabetes by magnetic resonance and intralipid infusion techniques.

Authors:  Ahmad Al-Mrabeh; Carl Peters; Kieren G Hollingsworth; Roy Taylor
Journal:  STAR Protoc       Date:  2021-03-02

8.  The Diabetes Remission Clinical Trial (DiRECT): protocol for a cluster randomised trial.

Authors:  Wilma S Leslie; Ian Ford; Naveed Sattar; Kieren G Hollingsworth; Ashley Adamson; Falko F Sniehotta; Louise McCombie; Naomi Brosnahan; Hazel Ross; John C Mathers; Carl Peters; George Thom; Alison Barnes; Sharon Kean; Yvonne McIlvenna; Angela Rodrigues; Lucia Rehackova; Sviatlana Zhyzhneuskaya; Roy Taylor; Mike E J Lean
Journal:  BMC Fam Pract       Date:  2016-02-16       Impact factor: 2.497

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.